Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 4.29
SRPT's Cash to Debt is ranked lower than
63% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. SRPT: 4.29 )
Ranked among companies with meaningful Cash to Debt only.
SRPT' s Cash to Debt Range Over the Past 10 Years
Min: 4.29  Med: 10000.00 Max: No Debt
Current: 4.29
F-Score: 1
Z-Score: -4.10
M-Score: 225.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -18458.01
SRPT's Operating margin (%) is ranked lower than
95% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. SRPT: -18458.01 )
Ranked among companies with meaningful Operating margin (%) only.
SRPT' s Operating margin (%) Range Over the Past 10 Years
Min: -28680.87  Med: -215.28 Max: -71.16
Current: -18458.01
-28680.87
-71.16
Net-margin (%) -18394.57
SRPT's Net-margin (%) is ranked lower than
95% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. SRPT: -18394.57 )
Ranked among companies with meaningful Net-margin (%) only.
SRPT' s Net-margin (%) Range Over the Past 10 Years
Min: -27020  Med: -286.12 Max: -4.93
Current: -18394.57
-27020
-4.93
ROE (%) -97.62
SRPT's ROE (%) is ranked lower than
81% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. SRPT: -97.62 )
Ranked among companies with meaningful ROE (%) only.
SRPT' s ROE (%) Range Over the Past 10 Years
Min: -309.2  Med: -76.40 Max: -16.44
Current: -97.62
-309.2
-16.44
ROA (%) -78.45
SRPT's ROA (%) is ranked lower than
82% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. SRPT: -78.45 )
Ranked among companies with meaningful ROA (%) only.
SRPT' s ROA (%) Range Over the Past 10 Years
Min: -93.53  Med: -59.76 Max: -4.62
Current: -78.45
-93.53
-4.62
ROC (Joel Greenblatt) (%) -489.46
SRPT's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. SRPT: -489.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SRPT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -978.9  Med: -532.73 Max: -294.07
Current: -489.46
-978.9
-294.07
Revenue Growth (3Y)(%) -52.10
SRPT's Revenue Growth (3Y)(%) is ranked lower than
84% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. SRPT: -52.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SRPT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -63.2  Med: 10.50 Max: 383.5
Current: -52.1
-63.2
383.5
EBITDA Growth (3Y)(%) 26.60
SRPT's EBITDA Growth (3Y)(%) is ranked higher than
82% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. SRPT: 26.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SRPT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -36.3  Med: 1.65 Max: 43.4
Current: 26.6
-36.3
43.4
EPS Growth (3Y)(%) 216.50
SRPT's EPS Growth (3Y)(%) is ranked higher than
99% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. SRPT: 216.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SRPT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -62.7  Med: -1.40 Max: 216.5
Current: 216.5
-62.7
216.5
» SRPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

SRPT Guru Trades in Q1 2015

Jim Simons 396,539 sh (+141.38%)
Steven Cohen 1,702,200 sh (+9.73%)
Columbia Wanger 3,272,400 sh (unchged)
Steven Cohen 174,900 sh (unchged)
» More
Q2 2015

SRPT Guru Trades in Q2 2015

Columbia Wanger 3,532,677 sh (+7.95%)
Steven Cohen 174,900 sh (unchged)
Jim Simons 295,178 sh (-25.56%)
Steven Cohen 936,600 sh (-44.98%)
» More
Q3 2015

SRPT Guru Trades in Q3 2015

Paul Tudor Jones 24,042 sh (New)
Jim Simons 507,738 sh (+72.01%)
Steven Cohen 910,370 sh (-2.80%)
Columbia Wanger 2,133,684 sh (-39.60%)
» More
Q4 2015

SRPT Guru Trades in Q4 2015

Columbia Wanger 1,164,690 sh (-45.41%)
Jim Simons 188,578 sh (-62.86%)
» More
» Details

Insider Trades

Latest Guru Trades with SRPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.97
SRPT's P/B is ranked lower than
71% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 2.56 vs. SRPT: 3.97 )
Ranked among companies with meaningful P/B only.
SRPT' s P/B Range Over the Past 10 Years
Min: 2  Med: 4.95 Max: 234
Current: 3.97
2
234
P/S 17875.10
SRPT's P/S is ranked lower than
99.99% of the 1127 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. SRPT: 17875.10 )
Ranked among companies with meaningful P/S only.
SRPT' s P/S Range Over the Past 10 Years
Min: 0  Med: 24.92 Max: 17307.86
Current: 17875.1
0
17307.86
Current Ratio 3.24
SRPT's Current Ratio is ranked lower than
60% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. SRPT: 3.24 )
Ranked among companies with meaningful Current Ratio only.
SRPT' s Current Ratio Range Over the Past 10 Years
Min: 0.76  Med: 7.53 Max: 36.25
Current: 3.24
0.76
36.25
Quick Ratio 3.24
SRPT's Quick Ratio is ranked lower than
57% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SRPT: 3.24 )
Ranked among companies with meaningful Quick Ratio only.
SRPT' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 7.53 Max: 36.25
Current: 3.24
0.76
36.25
Days Sales Outstanding 918.55
SRPT's Days Sales Outstanding is ranked lower than
100% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. SRPT: 918.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
SRPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.22  Med: 87.87 Max: 161.87
Current: 918.55
28.22
161.87

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.27
SRPT's Price/Net Cash is ranked higher than
66% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: 5.77 vs. SRPT: 12.27 )
Ranked among companies with meaningful Price/Net Cash only.
SRPT' s Price/Net Cash Range Over the Past 10 Years
Min: 3.03  Med: 6.41 Max: 72.6
Current: 12.27
3.03
72.6
Price/Net Current Asset Value 7.84
SRPT's Price/Net Current Asset Value is ranked higher than
71% of the 849 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. SRPT: 7.84 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SRPT' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.95  Med: 6.24 Max: 42
Current: 7.84
2.95
42
Price/Tangible Book 4.05
SRPT's Price/Tangible Book is ranked higher than
72% of the 1004 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. SRPT: 4.05 )
Ranked among companies with meaningful Price/Tangible Book only.
SRPT' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.41  Med: 4.87 Max: 474
Current: 4.05
2.41
474
Earnings Yield (Greenblatt) (%) -44.22
SRPT's Earnings Yield (Greenblatt) (%) is ranked lower than
84% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. SRPT: -44.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SRPT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -53.7  Med: 0.00 Max: 82
Current: -44.22
-53.7
82

More Statistics

Revenue(Mil) $10
EPS $ -4.83
Beta0.89
Short Percentage of Float28.13%
52-Week Range $10.20 - 41.97
Shares Outstanding(Mil)45.27

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 93 249 382
EPS($) -4.92 -3.46 -1.62 -0.16
EPS without NRI($) -4.92 -3.46 -1.62 -0.16

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:AB3A.Germany,
Sarepta Therapeutics Inc was incorporated in the State of Oregon on July 22, 1980. The Company discovers and develops RNA-based therapeutics for the treatment of rare and infectious diseases. Its product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The Company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases.
» More Articles for SRPT

Headlines

Articles On GuruFocus.com
Sarepta Therapeutics Inc (SRPT) Will File NDA; Analysts Have Mixed Ratings May 20 2015 
Wednesday’s Pre-Market Insights: Yahoo! Inc. (YHOO), Sarepta Therapeutics Inc (SRPT), Time Warner May 20 2015 
Steven Cohen Keeps on Buying Biotechnological Companies May 04 2015 
Ebola: Is The Cure Out There? Oct 14 2014 
Insiders Are Buying Fate Therapeutics Oct 09 2013 

More From Other Websites
The Zacks Analyst Blog Highlights: Regeneron, Alexion, CTI BioPharma, BioCryst and Sarepta Feb 11 2016
Relypsa: This Biotech Just Released Stunning Data Feb 10 2016
Biotech Stock Roundup: Alexion, Regeneron Miss Estimates; Setback for CTI BioPharma Feb 10 2016
Sarepta Hits 52-Week Low; Eteplirsen Review Period Extended Feb 09 2016
Sarepta Therapeutics Dropped 10% Following FDA News Feb 08 2016
Sarepta's Duchenne drug decision delayed: Why it could help win approval Feb 08 2016
[$$] FDA Extends Sarepta's Muscular Dystrophy Drug Deadline Feb 08 2016
Sarepta says FDA delays decision on muscle-wasting disorder drug Feb 08 2016
Sarepta Therapeutics Receives Notification of PDUFA Extension for Eteplirsen Feb 08 2016
Will Sarepta reverse after steep drop? Feb 05 2016
It’s Time to Buy This Biotech Gem Feb 04 2016
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Feb 02 2016
Top 10 BioFlash stories in January: Duchenne news dominates once again Feb 01 2016
3 Key FDA Decisions Expected in February Jan 31 2016
Structural Volatility Won't End For Several Years, Derivatives Strategist Says Jan 27 2016
Bragar Eagel & Squire, P.C. Is Investigating the Officers and Directors of Sarepta Therapeutics,... Jan 26 2016
Duchenne drug by Cambridge's Catabasis looks safe in early trial Jan 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK